16th Annual Cardiovascular Update Conference
February 6th and 7th from 8:00 am - 5:00 pm
For details visit: Registration Page

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • Is Occupational Physical Work Exposure a Risk Factor For ATTRwt-CM?
    In a registry-based study, an association was found between transthyretin wild-type amyloid cardiomyopathy (ATTRwt-CM) and occupational upper-body mechanical stress, along with a greater burden of orthopedic and cardiovascular comorbidities including increased cardiovascular mortality among patients with ATTRwt-CM. The hypothesis-generating findings were published Feb. 24 in JACC: Advances.
  • Nonobstructive HCM Treatment: Differential Effect of Bisoprolol vs. Verapamil
    Bisoprolol but not verapamil reduced peak oxygen consumption (pVO2) in patients with nonobstructive hypertrophic cardiomyopathy (HCM), according to research published March 3 in JACC.
  • Is Progression of Myocardial Fibrosis a Risk Indicator in HCM?
    Myocardial fibrosis increased over time in patients with hypertrophic cardiomyopathy (HCM), as assessed by late gadolinium enhancement (LGE) on follow-up cardiac MR, suggesting a higher risk for adverse outcomes, including all-cause mortality, hospitalization and stroke, according to research published Feb. 20 in JACC: Cardiovascular Imaging.
  • Your ACC Urges Reclassification of APRN, PA Degrees as Professional
    The U.S. Department of Education has categorized APRN and PA clinicians as "graduate" students rather than "professional" students under the One Big Beautiful Bill Act, lowering their federal loan limits.
  • Extended DAPT in Multivessel CAD: Less Ischemia Without a Major Bleeding Penalty
    The DAPT-MVD (Dual Antiplatelet Therapy in Patients With Coronary Multi-Vessel Disease) trial was a multicenter, randomized, open-label study in China designed to assess whether extending dual antiplatelet therapy (DAPT) beyond 12 months provides additional benefit for patients with multivessel coronary artery disease (CAD)...